Exact Sciences Corporation stockholders have approved the proposed acquisition by Abbott, with over 99% of votes cast in favor of the transaction. The acquisition is expected to close before the end of the second calendar quarter of 2026, granting Exact Sciences stockholders $105.00 in cash per share. Exact Sciences is a leading provider of cancer screening and diagnostic tests, including Cologuard® and Oncotype DX®.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Exact Sciences Stockholders Approve Acquisition by Abbott
Exact Sciences Corporation stockholders have approved the proposed acquisition by Abbott, with over 99% of votes cast in favor of the transaction. The acquisition is expected to close before the end of the second calendar quarter of 2026, granting Exact Sciences stockholders $105.00 in cash per share. Exact Sciences is a leading provider of cancer screening and diagnostic tests, including Cologuard® and Oncotype DX®.